Epidemiology of Vitiligo – A Dual Population-Based Approach

References

• Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE; Vitiligo Working Group. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017;77(1):1–13. doi:10.1016/j.jaad.2016.10.04828619550
   PubMed Web of Science ®Google Scholar
• Elbuluk N, Ezzedine K. Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients. Dermatol Clin. 2017;35(2):117–128. doi:10.1016/j.det.2016.11.00228317521
   PubMed Web of Science ®Google Scholar
• Morrison B, Burden-Teh E, Batchelor JM, Mead E, Grindlay D, Ratib S. Quality of life in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2017;177(6):e338–e339. doi:10.1111/bjd.1593328869779
   PubMed Web of Science ®Google Scholar
• Radtke MA, Schäfer I, Gajur A, Langenbruch A, Augustin M. Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol. 2009;161(1):134–139. doi:10.1111/j.1365-2133.2009.09091.x19298268
   PubMed Web of Science ®Google Scholar
• Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological co-morbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2018;178(4):863–878. doi:10.1111/bjd.1604928991357
   PubMed Web of Science ®Google Scholar
• Augustin M, Gajur AI, Reich C, Rustenbach SJ, Schaefer I. Benefit evaluation in vitiligo treatment: development and validation of a patient-defined outcome questionnaire. Dermatology. 2008;217(2):101–106. doi:10.1159/00012899218451647
   PubMed Web of Science ®Google Scholar
• Marinho Fde S, Cirino PV, Fernandes NC. Clinical epidemiological profile of vitiligo in children and adolescents. An Bras Dermatol. 2013;88(6):1026–1028. doi:10.1590/abd1806-4841.2013221924474125
   PubMed Web of Science ®Google Scholar
• Afkhami-Ardekani M, Ghadiri-Anari A, Ebrahimzadeh-Ardakani M, Zaji N. Prevalence of vitiligo among type 2 diabetic patients in an Iranian population. Int J Dermatol. 2014;53(8):956–958. doi:10.1111/ijd.1214824134629
   PubMed Web of Science ®Google Scholar
• Al-Harbi M. Prevalence of depression in vitiligo patients. Skinmed. 2013;11(6):327–330.24517036
   PubMedGoogle Scholar
• Paradisi A, Tabolli S, Didona B, Sobrino L, Russo N, Abeni D. Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10.040 patients with vitiligo. J Am Acad Dermatol. 2014;71(6):1110–1116. doi:10.1016/j.jaad.2014.07.05025242557
   PubMed Web of Science ®Google Scholar
• Chen YT, Chen YJ, Hwang CY, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2015;29(7):1362–1369. doi:10.1111/jdv.1287025510261
   PubMed Web of Science ®Google Scholar
• Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018;57(10):1157–1164. doi:10.1111/ijd.1405529808541
   PubMed Web of Science ®Google Scholar
• Mohan GC, Silverberg JI. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2015;151(5):522–528. doi:10.1001/jamadermatol.2014.332425471826
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Silverberg NB. Association between vitiligo and atopic disorders: a pilot study. JAMA Dermatol. 2013;149(8):983–986. doi:10.1001/jamadermatol.2013.422823740223
   PubMed Web of Science ®Google Scholar
• Lee H, Lee MH, Lee DY, et al. Prevalence of vitiligo and associated comorbidities in Korea. Yonsei Med J. 2015;56(3):719–725. doi:10.3349/ymj.2015.56.3.71925837178
   PubMed Web of Science ®Google Scholar
• Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206–1212. doi:10.1111/j.1365-4632.2011.05377.x22458952
   PubMed Web of Science ®Google Scholar
• Richard MA, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the « OBJECTIFS PEAU » study. J Eur Acad Dermatol Venereol. 2018;32(11):1967–1971. doi:10.1111/jdv.1495929569785
   PubMed Web of Science ®Google Scholar
• Radtke MA, Schäfer I, Gajur AI, Augustin M. Clinical features and treatment outcomes of vitiligo from the patients’ perspective. results of a national survey in Germany. Dermatology. 2010;220(3):194–200. doi:10.1159/00027565720203472
   PubMed Web of Science ®Google Scholar
• Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I. Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. Br J Dermatol. 2011;165(4):865–873. doi:10.1111/j.1365-2133.2011.10436.x21623753
   PubMed Web of Science ®Google Scholar
• Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology. 2013;227(1):10–13. doi:10.1159/00035129223988406
   PubMed Web of Science ®Google Scholar
• Schäfer I, Rustenbach SJ, Zimmer L, Augustin M. Prevalence of skin diseases in a cohort of 48.665 employees in Germany. Dermatology. 2008;217(2):169–172. doi:10.1159/00013665618525204
   PubMed Web of Science ®Google Scholar
• Ständer S, Schäfer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a Cross-Sectional Study in a sample working population of 11.730. Dermatology. 2010;221(3):229–235. doi:10.1159/00031986220924157
   PubMed Web of Science ®Google Scholar
• Zander N, Schäfer I, Radtke MA, Jacobi A, Heigel H, Augustin M. Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees. Arch Dermatol Res. 2017;309(5):349–356. doi:10.1007/s00403-017-1741-428405739
   PubMed Web of Science ®Google Scholar
• Busse R, Blümel M. Germany: health system review. Health Syst Transit. 2014;16(2):224.
   Google Scholar
• The National Association of Statutory Health Insurance Funds (GKV-Spitzenverband). Together we are 90 percent. annual report 2016. Available from: https://www.gkv-spitzenverband.de/media/dokumente/service_1/publikationen/geschaeftsberichte/GKV_GB2016_Englisch_barrierefrei_02.pdf. Accessed 824, 2018.
   Google Scholar
• Destatis - Federal Statistical Office. Population: Federal states, cut-off date, gender, age years. Available from: https://www-genesis.destatis.de/genesis/online/data;sid=AE5DC519704B990BC2FF46B3810229EA.GO_1_2?operation=abruftabelleBearbeiten&levelindex=1&levelid=1536226140277&auswahloperation=abruftabelleAuspraegungAuswaehlen&auswahlverzeichnis=ordnungsstruktur&auswahlziel=werteabruf&selectionname=12411-0013&auswahltext=%23SGES-GESW%2CGESM&werteabruf=Werteabruf. Accessed 906, 2018.
   Google Scholar
• Migayron L, Boniface K, Seneschal J. Vitiligo, from physiopathology to emerging treatments: a review. Dermatol Ther (Heidelb). 2020;10(6):1185–1198. doi:10.1007/s13555-020-00447-y32949337
   PubMed Web of Science ®Google Scholar
• Narayan VS, Uitentuis SE, Luiten RM, Bekkenk MW, Wolkerstorfer A. Patients’ perspective on current treatments and demand for novel treatments in vitiligo. J Eur Acad Dermatol Venereol. 2021;35(3):744–748. doi:10.1111/jdv.1692732893377
   PubMed Web of Science ®Google Scholar
• Wang X, Du J, Wang T, et al. Prevalence and clinical profile of vitiligo in China: a community-based study in six cities. Acta Derm Venereol. 2013;93(1):62–65. doi:10.2340/00015555-139722859054
   PubMed Web of Science ®Google Scholar
• Rork JF, Rashighi M, Harris JE. Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr. 2016;28(4):463–469. doi:10.1097/MOP.000000000000037527191524
   PubMed Web of Science ®Google Scholar
• Tatu AL, Ionescu MA. Multiple autoimmune syndrome type 3-thyroiditis, vitiligo and alopecia areata. Acta Endocrinol. 2017;13(1):124–125. doi:10.4183/aeb.2017.124
   Google Scholar
• van Geel N, Van Poucke L, Van de Maele B, Speeckaert R. Relevance of congenital melanocytic naevi in vitiligo. Br J Dermatol. 2015;172(4):1052–1057. doi:10.1111/bjd.1344425292332
   PubMed Web of Science ®Google Scholar
• Speeckaert R, Lambert J, Bulat V, Belpaire A, Speeckaert M, van Geel N. Autoimmunity in segmental vitiligo. Front Immunol. 2020;11:568447. doi:10.3389/fimmu.2020.56844733193342
   PubMed Web of Science ®Google Scholar
• Hartmann A, Bedenk C, Keikavoussi P, et al. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges. 2008;6(12):1053–1059. doi:10.1111/j.1610-0387.2008.06755.x18479500
   PubMed Web of Science ®Google Scholar